XML 82 R72.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Contingencies and Certain Commitments - Patent Litigation (Details) $ in Millions | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Sep. 30, 2022 patent | Aug. 31, 2022 patent | Jul. 31, 2022 patent | Dec. 31, 2017 patent defendant | Oct. 02, 2022 USD ($)
Gain Contingencies [Line Items] |  |  |  |  |
Threshold for disclosure of proceedings under environmental laws | $ |  |  |  |  | $ 1
Mektovi [Member] | Pfizer and Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |
Gain contingency, number of patents allegedly infringed upon |  | 6 |  |  |
Mektovi [Member] | Pfizer and Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] | Expiring 2030 [Member] |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |
Gain contingency, number of patents allegedly infringed upon |  | 2 |  |  |
Mektovi [Member] | Pfizer and Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] | Expiring 2033 [Member] |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |
Gain contingency, number of patents allegedly infringed upon |  | 2 |  |  |
Comirnaty direct sales and alliance revenues [Member] | ModernaTX Patent Infringement Case [Member] |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |
Loss contingency, number of patents allegedly infringed upon | 2 |  |  |  |
Comirnaty direct sales and alliance revenues [Member] | Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment Of Non-Infringement [Member] |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |
Loss contingency, number of patents found not infringed |  |  | 3 |  |
Eliquis alliance revenues and direct sales [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |
Gain contingency, number of patents allegedly infringed upon |  |  |  | 3 |
Number of defendants | defendant |  |  |  | 25 |
Number of patents allegedly infringed upon, expired December 2019 |  |  |  | 1 |

X
- Definition Gain Contingency, Number of Defendants + References No definition available. + Details
Name: | pfe_GainContingencyNumberofDefendants
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019 + References No definition available. + Details
Name: | pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Site Contingency, Regulatory Proceedings, Disclosure Threshold + References No definition available. + Details
Name: | pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_GainContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 30 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355 + Details
Name: | us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity was found not to have infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MektoviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerAndVersusSeveralGenericManufacturersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_ExpirationPeriodAxis=pfe_Expiring2030Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_ExpirationPeriodAxis=pfe_Expiring2033Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_ModernaTXPatentInfringementCaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |